Clinical experience with N-acetylcarnosine use in patients with age-related cataract

Clinical experience with N-acetyl carnosine use in patients with age-related cataract

Abstract. Background. A cataract is one of the most common leading to blindness diseases in the world. Pathological conditions associated with lens aging, including presbyopia and age-related cataract, have been known for a long time. That is why the World Health Organization supports large-scale studies on the drug's effectiveness for cataract prevention, especially those with antioxidants (2018). The study aimed to evaluate the effect of N-acetyl carnosine contained in Clarastill on the condition of the lens when used in patients with cataract for a long time (6 months). 

 

Materials and methods. The study lasted 6 months and covered

two groups. The first (control) group included 10 patients (18 eyes) aged 65.3 ± 3.0 years, the second group — 20 individuals (37 eyes)

aged 63.4 ± 5.0 years with a diagnosis of senile cataract. The study was conducted under the Declaration of Helsinki in 1964. 

Patients in the first group did not receive any drops and were only monitored for the entire period. Patients in the second group received Clarastill twice a day (local instillations into the conjunctival sac) for 6 months. 

 

Results. It was recorded that in the group of patients who used N-acetyl carnosine there was an improvement in visual acuity, results of achromatic visocontrastometry, Norn and Schirmer tests, as well as the condition of the lens according to the Lens Opacities Classification System III. 

 

Conclusions. Clarastill as a pharmaceutical product containing N-acetyl carnosine slows down cataract progression and, in some cases, significantly restores lens transparency in the initial (early) stages of cataract formation and can potentially delay surgery.

 

Keywords: age-related cataract; achromatic visocontrastometry; lens; Lens Opacities Classification System III; antioxidants

 

Visuspharm